

## FACULTY DISCLOSURE INFORMATION



### Hybrid Symposium “The GOG Highlight Reel” an Educational Series November 11, 2022

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An “**ineligible company**” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
<b>Speaker/Moderators</b>			
Robert Coleman, MD	Planning/Speaker		Honorarium: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis, Epsilon, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Bradley J. Monk, MD	Planning/Speaker		Honoraria: Consulting/Speaker: Agenus, Akeso, AstraZeneca, Aravive, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, Iovance, Karyopharm, Merck, McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, <del>Sandoz</del> Tesaro/GSK, VBL
Ramez Eskander, MD	Speaker		Advisory Board/Consulting Fee/Speaking: AstraZeneca; Merck; Clovis; GSK, Myriad
Kathleen Moore, MD	Speaker		Advisory board: AstraZeneca, Aravive, Blueprint, Alkermes, OnxXema, Eisai, GSK, Elevar, Genentech, Immunogen, Merck, VBL, Mersana, Myriad
Bhavana Pothuri, MD	Speaker		Research funding support/ Ad Board fees: AstraZeneca, Celis, Immunogen, Merck, Mersana, Seattle Genetics, Sutro, Takada, Tesaro, Clovis Oncology Advisory Board: Eisai, Lily, GOG Foundation
Leslie Randall, MD	Speaker		Consulting fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer

## FACULTY DISCLOSURE INFORMATION

Angeles Alvarez Secord, MD	Speaker		Advisory Board: Myriad Contracted clinical trial research: AbbVie, AstraZeneca, Boehringer, Clovis, Eisai, Immutep. Ltd, Merck, National Cancer Trial Network, Oncoquest, PharmaMar, Roche/Genentech, Seagen inc., Tesaro/GSK, VBL Therapeutics
Brian Slomovitz, MD	Speaker		Consultant: Abbvie, AstraZeneca, Clovis, GSK, Genentech, Merck, Myriad
Michelle Small	Staff	x	
Jill Reese	Staff	x	